Name 1

Response to Texas Nurse Practitioners Regulations Overview

Student’s Name

University

Course Code

Professor’s Name

Due Date
 Name 2

The detailed review of the legislation and standards for nurse practitioners in Texas is

quite informative. The collaborative model shows a sophisticated approach to healthcare

delivery, having to work within a 75-mile radius of a supervising physician. The strict control,

which includes a random examination of patient records by the physician, assures accountability

and patient safety.

From schooling and specialty to the application procedure, the thorough stages for

earning certification as an Advanced Practice Registered Nurse in Texas give a clear roadmap for

aspiring (Garber, 2019). The emphasis on a minimum GPA, RN experience, and a personal

interview highlights the dedication necessary for this advanced post.

The data on DEA licenses and the prescription monitoring program illuminates the

regulatory environment of banned drugs (McCauley et al., 2019). The restrictions, such as the

prohibition on prescribing Schedule 2 medications and the requirement for collaboration on

restricted substance prescriptions, are critical details.

Despite the lobbying for full practice authority, your final statements concerning the

persisting obstacles and limits encountered in Texas highlight an essential area of concern. The

potential advantages of relaxing constraints, particularly in light of the physician scarcity, could

improve healthcare access. Overall, your paper thoroughly explains Texas' regulatory

environment and the problems that nurse practitioners encounter.

 Name 3

References

Garber, K. M., & Chike-Harris, K. E. (2019). Nurse practitioners and virtual care: a 50-state

review of APRN telehealth law and policy. Telehealth and Medicine Today.

McCauley, J. L., Gilbert, G. H., Cochran, D. L., Gordan, V. V., Leite, R. S., Fillingim, R. B., ...

& National Dental PBRN Collaborative Group. (2019). Prescription drug monitoring

program use: national dental PBRN results. JDR Clinical & Translational Research, 4(2),

178-186.